Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > BUSINESS
BUSINESS
- Takeda, Teva Hook Up to Form Generic Joint Venture in Japan
November 30, 2015
- Eisai to Venture into Chinese Generic Market by Acquiring Local Firm
November 30, 2015
- Takeda’s MS Drug Copaxone Now Available; Actelion to Release Japan’s 1st Pediatric PAH Medicine in January
November 30, 2015
- JCR to Launch Cell Therapy for Post-Transplant Complication in February
November 30, 2015
- Viekirax Hits Japan Market, MHLW Orders Rare Label Revision upon Listing
November 27, 2015
- Eisai to Sell Food & Chemical Biz to Mitsubishi Chemical
November 27, 2015
- Sales of Candesartan AGs Miss Half-Year Target on Azilva Switches: ASKA Chief
November 26, 2015
- Japan’s 1st DTP-IPV Vaccine Containing Salk Vaccine to Be Available in December: Daiichi Sankyo
November 26, 2015
- Ex-Exec of Iwaki Subsidiary Embezzled 126 Million Yen
November 25, 2015
- Lilly Files Suit to Bar Launch of Sawai’s Evista Generic
November 24, 2015
- Eisai Gives Global Rights for Selective PDE4 Inhibitor E6005 to US Firm
November 24, 2015
- Kissei to License Endometriosis Treatment to Swiss Bioventure ObsEva
November 24, 2015
- Eisai to Transfer Clinical Diagnostic Business in Japan to Sekisui Chemical for 22.4 Billion Yen
November 24, 2015
- AZ, NCC Link for Non-Clinical Research Utilizing Mass Spectrometry Imaging
November 18, 2015
- Supreme Court Supports Patent Term Extension for Avastin
November 18, 2015
- Boehringer Exec Expects AMED’s Positive Impact on Company
November 18, 2015
- Japan Pharma Market Likely to Reach 9.7 Trillion Yen in 2022: Fuji Keizai
November 18, 2015
- Generic Makers’ Earnings Show Unabated Momentum 1 Year after Medical Fee Reform: Tally
November 17, 2015
- Otsuka Hopes Abilify Maintena Grabs 30% Share in Global Atypical Antipsychotic Market in 2018
November 17, 2015
- AZ Eyes Low Single-Digit Growth over Coming Years in Japan: Pres. Baertschi
November 16, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…